LA
MACK

LVW Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

LVW Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$80K – 222
2020
Q3 		$80K Buy
+20,000
New +$73.5K 0.02% 196
2020
Q2 		– Sell
-69,293
Closed -$149K – 216
2020
Q1 		$149K Sell
69,293
-1,514
-2% -$4.43K 0.04% 157
2019
Q4 		$223K Buy
70,807
+2,300
+3% +$9.21K 0.05% 170
2019
Q3 		$308K Buy
+68,507
New +$342K 0.08% 131

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

LVW Advisors's MACK Position: Q4 2020 in Review

LVW Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2020, closing a stake of 20,000 shares — an estimated $80K sold.

LVW Advisors first reported a position in MACK in Q3 2019 and held it in 4 quarters. The position peaked at $308K in Q3 2019. 40 funds tracked by Wall St. Rank hold MACK as of Q4 2020.

  • LVW Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • LVW Advisors sold 20,000 Merrimack Pharmaceuticals, Inc. shares in Q4 2020, an estimated $80K.
  • LVW Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2019 and held it in 4 quarters.
  • LVW Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $308K in Q3 2019.
  • 40 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2020.

Based on LVW Advisors's 13F filing for Q4 2020, filed 4 Feb 2021.